Bausch Health(us:BHC)
7.47
0.00%
Updated on 2024-12-23
Open:7.41
Close:7.47
High:7.51
Low:7.41
Pre Close:7.47
Volume:371281.00
Amount:2.77M
Turnover:0.10%
Shares:367.80M
MarketCap:2.75B
| Date | Total | Total Shares | Total Ratio | New | Increased | Decreased |
|---|---|---|---|---|---|---|
| 2024-06-30 | 267 | 281077610 | 76.59% | 38 | 56 | 110 |
| 2024-03-31 | 262 | 279821168 | 76.31% | 36 | 46 | 102 |
| 2023-12-31 | 258 | 286523229 | 78.45% | 41 | 50 | 96 |
| 2023-09-30 | 255 | 282209584 | 77.31% | 31 | 44 | 106 |
| 2023-06-30 | 265 | 262845691 | 72.20% | 34 | 60 | 105 |
| 2023-03-31 | 281 | 259236646 | 71.30% | 29 | 49 | 137 |
| 2022-12-31 | 322 | 287188516 | 79.36% | 46 | 50 | 169 |
| 2022-09-30 | 359 | 242424158 | 67.01% | 45 | 68 | 180 |
| date | orgName | total | ratio | changeShares | changeRatio |
|---|---|---|---|---|---|
| 2024-06-30 | Icahn Carl C | 34721118 | 9.46% | 0 | |
| 2024-06-30 | Paulson & Co. Inc. | 26439035 | 7.20% | 0 | |
| 2024-06-30 | Goldentree Asset Management Lp | 22437028 | 6.11% | -5207931 | -18.84% |
| 2024-06-30 | Nomura Holdings Inc | 19370000 | 5.28% | 4000000 | 26.02% |
| 2024-06-30 | National Bank Of Canada /Fi/ | 15667303 | 4.27% | 6009 | 0.04% |
| 2024-06-30 | Healthcare Of Ontario Pension Plan Trust Fund | 13000000 | 3.54% | 0 | |
| 2024-06-30 | Hudson Bay Capital Management Lp | 11500000 | 3.13% | -250000 | -2.13% |
| 2024-06-30 | Royal Bank Of Canada | 11460993 | 3.12% | -255052 | -2.18% |
| 2024-06-30 | Vanguard Group Inc | 11440913 | 3.12% | -273080 | -2.33% |
| 2024-06-30 | Franklin Resources Inc | 11398547 | 3.11% | -4452635 | -28.09% |
About
Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada.
Address:2150 St. Elzéar Boulevard West
Website:http://www.bauschhealth.com
Market Movers